Morehouse School of Medicine Appoints Dr. Joseph A. Tyndall As Dean And Executive Vice President For Health Affairs
Share Article
University of Florida Medical School Academic Leader, Emergency Medicine Chair and Trauma Researcher to Assume Leadership Role July 1. ATLANTA (PRWEB) May 11, 2021 Dr. Joseph Adrian Tyndall has been appointed Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine (MSM) reporting to President Valerie Montgomery Rice, MD, the institution announced today. Dr. Tyndall will be responsible for the day-to-day operations of the academic programs, as well as executing on the institution’s strategic plan. He will also assume leadership of Morehouse Healthcare and its world-class team of clinicians.
Share this article
ROSEMONT, Ill., May 6, 2021 /PRNewswire/ Dr. Mark H. Getelman has been named the
Arthroscopy Association of North America (AANA) President for 2021-2022 term. Dr. Getelman recently completed his terms as second and first Vice President and has been an active, multicommittee member of AANA for over 20 years. As a fellowship-trained orthopaedic surgeon, Dr. Getelman practices out of the Southern California Orthopedic Institute (SCOI) headquartered in Van Nuys, California.
Dr. Getelman previously served on the Executive Committee as Secretary of the Board of Directors for AANA, an international professional organization of more than 6,500 orthopaedic surgeons who are committed to advancing the field of minimally invasive orthopaedic surgery to improve patient outcomes. Dr. Getelman has also served as a member of the association s Education Committee as well as serving as Chairman of both the Fellowship and Development Committees. He began his term as President a
Should COVID Shots for Teens Go to Developing Countries? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share this article
PALO ALTO, Calif., May 5, 2021 /PRNewswire/
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA).
GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation as well as cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint.
Share this article
Share this article
JACKSONVILLE, Fla., May 5, 2021 /PRNewswire/ An organization that serves individuals with mental health and substance use disorders and a specialty care clinic that utilizes clinical health workers to connect underserved patients with community resources are among nine recipients of the Florida Blue Foundation s annual Sapphire Awards. The honorees will share $500,000 in funding that will allow them to continue to focus on innovative ideas and programs to meet local community needs.
The Florida Blue Foundation, the philanthropic arm of the state s Blue Cross Blue Shield plan, announced the nine honorees at its annual Sapphire Awards ceremony, which was held virtually on May 4. Each of the individuals, programs and organizations are making a meaningful impact in their communities related to three key drivers of health: mental well-being, health equity or food security.